:quality(90)/p7i.vogel.de/wcms/0b/bc/0bbcb1b610cf74d94922a9d89a037e88/0129755383v4.jpeg "Data Privacy & Consent for Marketing – Vogel Communications Group")
Vogel Communications Group Data Privacy and Consent Policies
As of December 8, 2025, Vogel Communications Group GmbH & Co. KG (Vogel) prioritizes the responsible handling of personal data, processing it in compliance with applicable data protection regulations, including the EU General Data Protection Regulation (GDPR). This article details the company’s policies regarding data privacy, consent for advertising purposes, and user rights.
Data Privacy Commitment
Vogel, located at Max-Planck-Str. 7-9, 97082 Würzburg, Germany, acts as the controller for the processing of personal data collected through its websites and services. For questions or concerns regarding data protection, individuals can contact Vogel’s privacy officer at datenschutz@vogel.de. Vogel’s full privacy policy provides detailed information on data processing practices.
Consent for Advertising Purposes
Vogel seeks explicit consent for the use of data for advertising purposes. By granting consent, users agree to allow Vogel Communications Group, including its affiliated companies (as defined by Sections 15 ff. AktG), to use their email address to send editorial newsletters. A list of associated companies can be found here.
Newsletter Content
These newsletters cover a range of products and services, including:
- Specialist magazines and books
- Events and trade fairs
- Event-related products and services
- Print and digital media offers
- Other editorial newsletters
- Competitions and lead campaigns
- Online and offline market research
- Specialist web portals
- E-learning offers
If a personal telephone number is collected, it may be used for offers related to the above products and services, as well as for market research.
Data Comparison for Marketing
Consent too extends to the processing of email addresses and telephone numbers for data comparison with selected advertising partners, such as LinkedIn, Google, and Meta. Vogel may transmit hashed data to these partners to determine if the user is a member of their respective portals. This process supports:
- Retargeting (upselling, crossselling, and customer loyalty)
- Generation of lookalike audiences for new customer acquisition
- Exclusion criteria for ongoing advertising campaigns
Further information on data comparison for marketing purposes is available in Vogel’s data protection declaration.
Access to Protected Content
Accessing protected content on Vogel Communications Group portals, including those of its affiliated companies, may require additional registration data. In exchange for free access to editorial content, this data may be used for the purposes outlined in the consent agreement, excluding data comparison for marketing purposes.
Right to Withdraw Consent
Users have the right to withdraw their consent at any time. Withdrawal does not affect the lawfulness of processing based on consent given prior to the revocation. Consent can be revoked using the contact form. Users can also unsubscribe from individual newsletters by clicking the unsubscribe link at the end of the email. Detailed information regarding the right of withdrawal and its exercise can be found in Vogel’s data protection declaration, in the editorial newsletter section.
Company Information
Vogel Communications Group GmbH & Co. KG is registered at the following addresses:
- Max-Planck-Str. 7/9, 97082 Würzburg
- Postadresse: 97064 Würzburg
- Registergericht Würzburg, HRA 245
- Umsatzsteueridentifikationsnummer: DE 169 343 403
The Komplementär GmbH is Vogel Communications Group Verwaltungs GmbH, registered at Registergericht Würzburg, HRB 10.
Geschäftsführer (Managing Directors): Matthias Bauer (Vorsitz), Dennis Hirthammer, Günter Schürger
For editorial content related to vogel-professional-education.de:
- Niels Bernau, Programmleiter Vogel Professional Education
- Julia Moßner, Leitung Aus- und Weiterbildungsmedien
Further information about Vogel Communications Group can be found at www.vogel.de.
Related reading
- Nancy Mace’s Decade-Old Unproven Claim Resurfaces on Facebook
- Building a Startup in Colorado: The Reality of the ‘Missing Middle
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)